Among the five frequently mutated glioma genes (BRAF, IDH1, TP53, IDH1, and H3F3A), BRAF and H3F3A mutation rates continuously decreased as patient ages increased from pediatric to AYAs and to OAs. This evidence concerns the gene IDH1 and central nervous system cancer.